Topoisomerase inhibitor: Difference between revisions
No edit summary |
No edit summary |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{SI}} | {{SI}} | ||
{{ | {{CMG}} | ||
==Overview== | ==Overview== | ||
| Line 15: | Line 16: | ||
{{QuinoloneAntiBiotics}} | {{QuinoloneAntiBiotics}} | ||
{{Chemotherapeutic agents}} | {{Chemotherapeutic agents}} | ||
[[Category:Oncology]] [[Category:Antibiotics]] | [[Category:Oncology]] [[Category:Antibiotics]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 18:58, 17 August 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Topoisomerase inhibitors are chemotherapy agents designed to interfere with the action of topoisomerase enzymes (topoisomerase I and II), which are enzymes that control the changes in DNA structure by catalyzing the breaking and rejoining of the phosphodiester backbone of DNA strands during the normal cell cycle.
In recent years, topoisomerase inhibitors have become popular targets for cancer chemotherapy treatments. It is thought that topoisomerase inhibitors block the ligation step of the cell cycle, and that topoisomerase I and II inhibitors interfere with the transcription and replication of DNA by upsetting proper DNA supercoiling.
A commonly prescribed class of topoisomerase inhibitors are fluoroquinolones.
- Topoisomerase I inhibitors: irinotecan, topotecan, camptothecin and lamellarin D
- Topoisomerase II inhibitors: amsacrine, etoposide, etoposide phosphate, teniposide and doxorubicin